Promising antidiabetic drug

We have started an interesting study with a promising antidiabetic drug. The drug is designed in the form of prolonged-action tablets, which action leads to increased insulin secretion. It is an innovative drug that is in the first phase of research when it is first used in humans. The first drug administrations are behind us, we continue with the next doses. We plan to complete 1 part of SAD (single ascending dose) at the end of July.

More and more people are suffering from type II diabetes, it is a civilization disease, we challenge it with new drugs in the hope of full success. The BRG Center hopes to participate in many such Polish projects.

Go back

News

Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

BioResearch is following  new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic..

Read more …

BRG update on COVID-19

Dear Investigators and Researchers.
In recent days, the whole world is providing heroic fight with the SARS-CoV-2 virus.

Read more …

International Clinical Trials Day

On 28th of June, 2019 we attended the annual conference on the occassion of International Clinical Trials Day titled "On the verge of changes".

Read more …

TransCelerate accreditation

To improve our trainings system, we joined „GCP Mutual Recognition Program" and were accredited by TransCelerate Biopharma Inc

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲